公开(公告)号：US20240343713A1

公开(公告)日：2024-10-17

申请号：US18436936

申请日：2024-02-08

Applicant: Geron Corporation

Inventor： Manoj Kumar Khera ,  Ajay Soni

IPC: C07D405/10 ,  A61K31/4155 ,  A61P35/00 ,  C07D403/10

CPC classification number: C07D405/10 ,  A61K31/4155 ,  A61P35/00 ,  C07D403/10

Abstract: Provided are telomerase inhibitor compounds. Some compounds include a lactone or lactam group that is covalently bonded to a phenyl ring, which is itself bonded to a pyrazole group. In other cases, a sulfonamide-containing moiety is covalently bonded to a phenyl ring, which is itself bonded to a pyrazole group. In some embodiments, the telomerase inhibitor compound has a vinyl sulfonamide group bonded to an amide moiety and an aromatic group. In other cases, the inhibitor compound has an isothiazolidine 1,1-dioxide core that is bonded to a phenyl group. Aspects of the invention also include pharmaceutical compositions comprising the subject telomerase inhibitor compounds, as well as methods of treating telomerase-related diseases or conditions.

公开(公告)号：US20240336638A1

公开(公告)日：2024-10-10

申请号：US18571763

申请日：2022-06-28

Applicant: Guoqin ZHUGE ,  Xiaoqin LI

Inventor： Xiaoqin LI ,  Jianfang CHEN

IPC: C07F7/18 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/695 ,  A61P7/02 ,  A61P9/10 ,  C07C69/757 ,  C07D213/16 ,  C07D233/58 ,  C07D233/68 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10

CPC classification number: C07F7/1804 ,  A61K31/216 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61K31/695 ,  A61P7/02 ,  A61P9/10 ,  C07C69/757 ,  C07D213/16 ,  C07D233/58 ,  C07D233/68 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10

Abstract: An imidazole compound as shown in formula I or a pharmaceutically acceptable salt and an intermediate thereof. The imidazole compound as shown in formula I can significantly inhibit AA-induced platelet aggregation, improves MCAO/R-induced rat cerebral ischemia injury, has excellent metabolic stability, and can improve the distribution of a drug within the brain tissue, such that the pharmacodynamic activity of the imidazole compound in treatment of dyskinesia associated with acute thrombotic cerebral infarction and cerebral infarction is improved.

公开(公告)号：US20240334822A1

公开(公告)日：2024-10-03

申请号：US18732952

申请日：2024-06-04

Applicant: SAMSUNG SDI CO., LTD.

Inventor： Yongtak YANG ,  Dong Min KANG ,  Hyung Sun KIM ,  Jinhyun LUI ,  Seungin PARK ,  Jaejin OH ,  Sung-Hyun JUNG ,  Ho Kuk JUNG ,  Youngkyoung JO ,  Pyeongseok CHO ,  Dalho HUH

IPC: H10K85/60 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D487/04 ,  C07F15/00 ,  C09K11/06 ,  H10K50/11 ,  H10K85/30 ,  H10K101/10

CPC classification number: H10K85/654 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D487/04 ,  C07F15/0033 ,  C07F15/0086 ,  C09K11/06 ,  H10K85/342 ,  H10K85/346 ,  H10K85/6572 ,  H10K85/6574 ,  C09K2211/1029 ,  C09K2211/1044 ,  C09K2211/185 ,  H10K50/11 ,  H10K2101/10

Abstract: A composition for an organic optoelectronic device, an organic optoelectronic device, and a display device, the composition including a first compound; a second compound; and a third compound, the first compound, the second compound, and the third compound are different from each other, the first compound is represented by Chemical Formula I, the second compound is represented by Chemical Formula II or Chemical Formula III, and the third compound is represented by Chemical Formula II or Chemical Formula III,

公开(公告)号：US20240334821A1

公开(公告)日：2024-10-03

申请号：US18614841

申请日：2024-03-25

Applicant: UDC IRELAND LIMITED

Inventor： Thomas Schafer ,  Patrice Bujard ,  Jonathan Rogers ,  Kristina Bardon

IPC: H10K85/60 ,  C07D239/26 ,  C07D403/10 ,  C09K11/06 ,  H10K50/11

CPC classification number: H10K85/654 ,  C07D239/26 ,  C07D403/10 ,  C09K11/06 ,  C09K2211/1018 ,  H10K50/11 ,  H10K85/6565

Abstract: Disclosed are electroluminescent devices that comprise organic layers that contain certain organic compounds containing one ore more pyrimidine moieties. The organic compounds containing one ore more pyrimidine moieties are suitable components of blue-emitting, durable, organo-electroluminescent layers. The electroluminescent devices may be employed for full color display panels in for example mobile phones, televisions and personal computer screens.

公开(公告)号：US20240298531A1

公开(公告)日：2024-09-05

申请号：US18563304

申请日：2023-03-16

Applicant: LG CHEM, LTD.

Inventor： Jae Tak LEE ,  Jung Min YOON ,  Heekyung YUN ,  Su Jin HAN ,  Dong Uk HEO ,  Sung Kil HONG

IPC: H10K85/60 ,  C07D403/10 ,  C09K11/06 ,  H10K50/16 ,  H10K50/17

CPC classification number: H10K85/654 ,  C07D403/10 ,  C09K11/06 ,  H10K85/615 ,  C09K2211/1018 ,  H10K50/16 ,  H10K50/171

Abstract: Provided is a heterocyclic compound of Chemical Formula 1:



[Chemical Formula 1]








wherein: L1 is a direct bond or a substituted or unsubstituted arylene group; L2 is a substituted or unsubstituted arylene group; two or more of X1 to X3 are N and any remaining is CR′; Np is Chemical Formula 2:



[Chemical Formula 2]








wherein: the dotted lines “------” are positions of attachment of Chemical Formula 2 where one is bonded to L1 and the other is bonded to L2 of Chemical Formula 1; and the other substituents are as defined in the specification; and an organic light-emitting device including the same. A light emitting device that includes the compound of Chemical Formula 1 in an organic material layer exhibits high efficiency and long service life.

公开(公告)号：US12077510B2

公开(公告)日：2024-09-03

申请号：US17653256

申请日：2022-03-02

Applicant: Sumitomo Pharma Co., Ltd.

Inventor： Seiji Hori ,  Futoshi Hasegawa ,  Daisuke Urabe ,  Hirotaka Kurebayashi

IPC: C07D239/48 ,  C07D239/47 ,  C07D239/49 ,  C07D403/10 ,  C07D403/12 ,  A61K31/505 ,  A61K31/506

CPC classification number: C07D239/48 ,  C07D239/47 ,  C07D239/49 ,  C07D403/10 ,  C07D403/12 ,  A61K31/505 ,  A61K31/506 ,  Y02P20/55

Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof:




wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

公开(公告)号：US12060345B2

公开(公告)日：2024-08-13

申请号：US16858257

申请日：2020-04-24

Applicant: IDIENCE CO., LTD.

Inventor： Keuncheol Ryu ,  Seoktaek Lee ,  Hanna Seo ,  Hyeran Yang ,  Wonje Seong ,  Jinyoung Yoon

IPC: C07D403/10

CPC classification number: C07D403/10

Abstract: The present application provides a method of preparing 4-[3-(3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one, or a pharmaceutically acceptable salt thereof, intermediates in the preparation thereof, methods of preparing the intermediates, and compositions and products comprising 4-[3-(3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one made from the methods that result in high purity and yield.

公开(公告)号：US20240262809A1

公开(公告)日：2024-08-08

申请号：US18557775

申请日：2022-04-26

Applicant: LG CHEM, LTD.

Inventor： In Ae RYU ,  Ju Young LEE ,  Joo Yong YOON ,  Seok Ju LEE ,  Ah Byeol PARK ,  Ki Dae KIM ,  Hui Rak JEONG

IPC: C07D403/10

CPC classification number: C07D403/10

Abstract: The present invention relates to a novel method for preparing an intermediate of Chemical Formula 2, wherein the intermediate can be effectively used in the synthesis of a xanthine oxidase inhibitor.

公开(公告)号：US20240239754A1

公开(公告)日：2024-07-18

申请号：US18558188

申请日：2021-07-30

Applicant: GUANGDONG UNIVERSITY OF TECHNOLOGY

Inventor： Yanping HUO ,  Yudong WEN ,  Hongping XIANG ,  Shaomin JI ,  Wencheng CHEN ,  Jiye LUO ,  Liang GAO ,  Jingwei ZHAO

IPC: C07D235/02 ,  C07D403/10 ,  C07D403/14 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C08F2/48

CPC classification number: C07D235/02 ,  C07D403/10 ,  C07D403/14 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C08F2/48

Abstract: Provided are a phenanthroimidazole derivative, and a preparation method therefor, and an application thereof. The phenanthroimidazole derivative has a structural formula as shown in Formula (I), R being an electron donor group,




wherein by taking a phenanthroimidazole group containing a trifluoromethyl phenyl group as an electron acceptor, and in virtue of the properties of the specific electron donor group R, the phenanthroimidazole derivative containing a light-absorbing photosensitive group of a series D-π-A structure is synthesized, and can be used as a photoinitiator, which is used in the technical field of UV light-curing systems or 3D printing. The phenanthroimidazole derivative has a certain conjugated chain length, can increase its photon absorption cross section, can serve as a photoinitiator of a UV light-curing system, for initiating a polymerization reaction at a wavelength of 365 nm, and has high polymerization efficiency; a double bond conversion rate of the phenanthroimidazole derivative in 50 s is up to 88.34%.

公开(公告)号：US20240239752A1

公开(公告)日：2024-07-18

申请号：US18286615

申请日：2022-04-14

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Zhao Dang ,  Krishnan Raman

IPC: C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.